April 02, 2014
1 min read

BioLight subsidiary files IND for study of glaucoma treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ViSci, a wholly owned subsidiary of BioLight, has filed an investigational new drug application with the U.S. Food and Drug Administration regarding a potential study of a glaucoma treatment, according to a press release.

The company is applying to conduct a phase 1/2a clinical study of a proprietary subconjunctival latanoprost controlled-release insert for the treatment of glaucoma.

If approved, the study will be conducted over the course of 3 months at up to seven different centers in the U.S. and include 68 glaucoma patients, according to the release.

The study’s primary outcomes are the safety and efficacy of different doses of the insert containing latanoprost, the release said.